![]() |
|
A study by Satizabal et al published
in the NEJM found that dementia rates
fell steadily over the past three decades, likely due to declining rates of
heart disease.
The study analyzed data
collected since 1975 from the Framingham Heart Study
and included 5205 persons 60 years of age or older. The authors compared interactions
between epoch and age, sex, apolipoprotein E ε4 status, educational level, as
well as the effects of vascular risk factors such as cardiovascular disease on the
prevalence of dementia.
The 5-year age-and sex-adjusted
cumulative hazard rates for dementia were 3.6 per 100 persons during the first
epoch (late 1970s and early 1980s), 2.8 per 100 persons during the second epoch
(late 1980s and early 1990s), 2.2 per 100 persons during the third epoch (late
1990s and early 2000s), and 2.0 per 100 persons during the fourth epoch (late
2000s and early 2010s). Relative to the incidence during the first epoch, the
incidence declined by 22%, 38%, and 44% during the second, third, and fourth
epochs, respectively. This risk reduction was observed only among persons who
had at least a high school diploma. The prevalence of most vascular risk
factors (except obesity and diabetes) and the risk of dementia associated with
stroke, atrial fibrillation, or heart failure have decreased over time, but
none of these trends completely explain the decrease in the incidence of the
disease.
The authors concluded that the
incidence of dementia has declined over the course of three decades.
N Engl J Med 2016; 374:523-532
|
Friday, April 1, 2016
Decades long decline in Dementia
Tuesday, March 1, 2016
Cancer death rate has fallen in the United States
Each year, the American Cancer Society
(ACS) estimates the numbers of new cancer cases and deaths that will occur in
the United States in the current year and compiles the most recent data on
cancer incidence, mortality, and survival.
The ACS collects and reports data from
several registries such as SEER, CDC, NPCR, NACCR and NCHS. In 2016, 1,685,210 new cancer cases and
595,690 cancer deaths are projected to occur in the United States. Overall
cancer incidence trends are stable in women, but declining by 3.1% per year in
men (from 2009-2012), much of which is because of recent rapid declines in
prostate cancer diagnoses. The cancer
death rate has dropped by 23% since 1991, translating to more than 1.7 million
deaths averted through 2012. The decline is attributed to decreasing
smoking rates and advances in cancer detection, treatment and prevention.
Deaths from lung, breast, prostate, and colon/rectum cancers drove
overall declines. Death rates for female
breast cancer have declined 36% from peak rates in 1989, while deaths from
prostate and colorectal cancers have each dropped about 50% from their peak.
Meanwhile, lung cancer death rates declined 38% between 1990 and 2012 among
males and 13% between 2002 and 2012 among females, due to a decline in the use
of tobacco.
In spite of this progress, death rates
are increasing for cancers of the liver, pancreas, and uterine corpus. Among
children and adolescents (aged birth-19 years), brain cancer has surpassed
leukemia as the leading cause of cancer death because of the dramatic
therapeutic advances against leukemia.
Despite of these remarkable
improvements cancer remains the leading cause of death in 21 states, primarily
due to exceptionally large reductions in death from heart disease. Accelerating
progress against cancer requires novel approaches in diagnosis, treatment and the application of existing cancer control knowledge across all
segments of the population
CA: A Cancer J Clin Vol 66, 1, 7-30,
Jan-Feb 2016
Monday, February 1, 2016
One-third of all cancers maybe inherited
![]() |
|
Muci et al published in JAMA the results of a trial that suggests
that approximately one-third of all cancers are due to inherited genes.
The investigators
looked at data from 80 309 monozygotic and 123 382 same-sex dizygotic twin
individuals (N = 203 691) within the population-based registers of Denmark, Finland,
Norway, and Sweden, who were part of the Nordic Twin Study of Cancer.
Twins
were followed up a median of 32 years between 1943 and 2010. There were 50 990
individuals who died of any cause, and 3804 who emigrated and were lost to
follow-up.
The
main outcome was incident cancer and time-to-event analyses were used to
estimate familial risk.
A
total of 27 156 incident cancers were diagnosed in 23 980 individuals,
translating to a cumulative incidence of 32%. Cancer was diagnosed in both
twins among 1383 monozygotic (2766 individuals) and 1933 dizygotic (2866
individuals) pairs. Of these, 38% of monozygotic and 26% of dizygotic pairs
were diagnosed with the same cancer type.
The analysis of data found that overall heritability for cancer
was 33 percent among the entire study population, and significantly higher for
certain types of cancers. Significant
heritability was found in 58 percent of diagnosed skin melanomas, 57 percent of
prostate cancers, 43 percent of non-melanoma skin cancers, 39 percent of
ovarian cancers, 38 percent of kidney cancers, 31 percent of breast cancers and
27 percent of uterine cancers. In the
same study researchers identified a set of cancers in which genetics play a
very small role. This group includes lung cancer (18 percent), colon cancer (15
percent), rectal cancer (14 percent), and head and neck cancer (9 percent).”
In
this long-term follow-up study among Nordic twins, there was significant
familial risk for cancer overall and for specific types of cancer. This information about hereditary risks of
cancers may be helpful in patient education and cancer risk counseling.
|
Friday, January 1, 2016
Top Three Posts
During the last two years I uploaded 20 posts in my blog
Medical News Monthly. The top three in
order of viewing frequency were:
1. Ebola Outbreak
2. The Mediterranean Diet
3. WHO Report on Antimicrobial
Resistance
Most of the visitors were from the United States,
followed by Greece, Russia, France, Macedonia, Poland, Ireland, Ukraine,
Germany, Switzerland and India in that order.
Tuesday, December 1, 2015
SPRINT trial redefines blood pressure targets
More than 70 million people in the United States suffer from hypertension – which presently is defined by a systolic blood pressure of higher than 140 mm Hg and a diastolic of higher than 90 mm Hg. A landmark study called SPRINT (Systolic Blood Pressure Intervention Trial) challenges the accepted guidelines of optimum level for systolic blood pressure and provided information about benefits and shortcomings of intensive pharmacotherapy. The study was published in NEJM was interrupted nearly two years early, when it became apparent that lower blood pressure for most people over 50 prevented heart problems and deaths.
In the SPRINT trial, 14,692 patients
were assessed for eligibility, and 9361 individuals with a systolic blood
pressure of 130 mm Hg or higher and an increased cardiovascular risk, but
without diabetes, were randomly assigned in two groups; a systolic
blood-pressure target group of less than 120 mm Hg (intensive treatment) or a
target group of less than 140 mm Hg (standard treatment).
The primary outcomes were myocardial
infarction, other acute coronary syndromes, stroke, heart failure, or death
from cardiovascular causes.
At 1 year, the mean systolic blood
pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in
the standard-treatment group. The mean number of blood-pressure medications was
2.8 in the intensive-treatment group and 1.8 in the standard-treatment group. The intervention was stopped early after a
median follow-up of 3.26 years owing to a significantly lower rate of the
primary composite outcome in the intensive-treatment group than in the
standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with
intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89;
P<0.001). All-cause mortality was also significantly lower in the
intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003).
Investigators found that there were 27% fewer
deaths (155 compared with 210) and 38% fewer cases of heart failure (62
compared with 100) among patients who achieved the
systolic pressure target of 120 mm Hg than among those who achieved the current
140 mm Hg target.
The lower
relative risk of major cardiovascular events observed across subgroups defined
according to age, sex, race, medical history, and baseline blood pressure among
patients who achieved the systolic pressure target of 120 mm Hg in comparison
to those who achieved the currently recommended level of 140 mm Hg.
Rates of serious adverse events of
hypotension, syncope were 67% and 33% higher in the intensive therapy
group. Electrolyte abnormalities, and
acute kidney failure were noted but injuries due to falls surprisingly were not
more common, as had been feared among the elderly in the intensive-treatment
group.
The research indicated that among
patients over 50 at high risk for cardiovascular events who are not diabetics,
targeting a systolic blood pressure below the current guidelines of 140 or 150
mm Hg to less than 120 mm Hg, prevented heart disease and strokes and thus save
lives.
DOI:
10.1056/NEJMoa1511939
Subscribe to:
Posts (Atom)



